Table 3.

Cancer incidence in the 79 patients diagnosed with an insulinoma in Finland during 1980–2010, and in 316 matched controls, after the diagnosis of insulinoma.

Cancer type	Patients			Controls			Patients vs controls		P value
	n/n at risk	Incidence rate/10 000/year	95% CI	n/n at risk	Incidence rate/10 000/year	95% CI	Rate ratio	95% CI
Any cancer	13/77	135.66	78.77–233.63	32/300	74.59	52.75–105.48	1.82	0.96–3.47	0.065
Breast cancera	5/55	71.99	29.96–172.95	5/216	16.15	6.72–38.81	4.46	1.29–15.39	0.010
Kidney cancer	3/79	29.64	9.56–91.90	0/315	0.00	0.00–8.00	NA		<0.001
Lymphatic and haematopoietic cancers	2/79	19.74	4.94–78.93	9/315	19.76	10.28–37.97	1.00	0.22–4.62	0.999
Prostate cancerb	1/23	32.75	4.61–232.47	6/92	44.36	19.93–98.73	0.74	0.09–6.13	0.778
Colon cancer	0/78	0.00	0.00–36.06	4/312	8.74	3.28–23.28	0.00		0.346
Malignant melanoma	0/79	0.00	0.00–35.85	3/316	6.56	2.12–20.34	0.00		0.413
Gastric cancer	0/79	0.00	0.00–35.85	2/315	4.36	1.09–17.44	0.00		0.504
Lung and tracheal cancers	0/79	0.00	0.00–35.85	2/316	4.34	1.09–17.36	0.00		0.505
Ovarian cancera	0/55	0.00	0.00–51.44	2/220	6.31	1.58–25.21	0.00		0.502
Skin cancer (other than melanoma)	0/79	0.00	0.00–35.85	2/316	4.35	1.09–17.38	0.00		0.505
Other cancersc	3/79	29.78	9.60–92.33	6/315	13.12	5.90–29.21	2.27	0.57–9.07	0.233

Bold values indicate a statistically significant difference between the patients and the controls (P  < 0.05, Mantel–Haenszel method). When the Bonferroni correction for multiple comparisons is applied, a P value < 0.004 (<0.05/12) is considered statistically significant.

^aOnly females included; ^bOnly males included; ^cOther cancers in the patients included cancers of the thyroid gland, uterus, and pancreas (n = 1 each).

NA, not applicable.